Company Interview / Argenica Therapeutics (ASX: AGN) Investor Presentation

CEO Liz Dallimore shares how Argenica Therapeutics (ASX: AGN) is making significant strides as a clinical-stage drug development company focused on commercialising neuroprotective treatments to minimise brain damage following acute injuries such as stroke, traumatic brain injury (TBI), and hypoxic ischaemic encephalopathy with lead drug candidate, ARG-007.

ARG-007 is progressing through a phase two clinical trial in acute ischaemic stroke, with top-line data expected in early September. Dallimore notes that successful completion of this trial could catalyse significant value for the company, given the drug’s potential to address a multi-billion-dollar global market with no current neuroprotective competitors. The design of the trial, centred around patients undergoing thrombectomy and measuring infarct volume reduction, is carefully constructed to reflect real-world clinical settings and maximise the drug’s commercial viability.*The information contained in this event is general in nature and is not intended as advice. Before acting on information you've seen or heard at this event, you should seek professional financial advice that takes into account your personal circumstances. 

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD